Mesothelioma News and Research

RSS

Mesothelioma is a form of cancer that is almost always caused by previous exposure to asbestos. In this disease, malignant cells develop in the mesothelium, a protective lining that covers most of the body's internal organs. Most people who develop mesothelioma have worked on jobs where they inhaled asbestos particles, or have been exposed to high levels of asbestos fibers.

FDA grants fast track designation to Insilico's AI-designed mesothelioma drug candidate

Insilico Medicine ("Insilico"; HKEX: 3696), a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, today announced that ISM6331, a novel, potential best-in-class pan-TEAD inhibitor driven by Insilico's proprietary AI, has received Fast Track Designation (FTD) from the U.S.

29 Jul 2026

Bifidobacterium-based oral vaccine enhances anti-tumor immunity in clinical study

A novel oral vaccine platform using genetically engineered Bifidobacterium could enhance anti-tumor immunity.

14 Jul 2026

Study reports a counterintuitive new approach to treating mesothelioma

Mesothelioma is a rare but aggressive cancer, usually caused by exposure to asbestos. Inhaled asbestos fibers become lodged in the lungs, causing inflammation that can lead to tumor formation decades later. Worldwide, about 30,000 people are diagnosed with mesothelioma each year.

14 Jul 2026

Researchers develop new model to study aggressive melanomas

Researchers have created a powerful new cellular model to study rare tumors that are resistant to immunotherapies.

29 Jun 2026

AI accurately measures mesothelioma tumors for better treatment decisions

Physicians and researchers at the Netherlands Cancer Institute have developed an AI model that outperforms physicians at evaluating treatment response in pleural mesothelioma.

17 Jun 2026

Mesothelioma remains deadly despite declining asbestos exposure rates

Mesothelioma deaths and diagnoses continue to rise in the United States despite decades of asbestos regulation and reduced industrial use, according to a new national analysis from Sylvester Comprehensive Cancer Center, part of the University of Miami Miller School of Medicine.

11 Jun 2026

Hypoxia-gated AAV enables targeted treatment for advanced NSCLC

Adeno‑associated virus (AAV) vectors offer safety and durable expression but lack tumor specificity. This hypothesis proposes an NSCLC‑directed, hypoxia‑responsive AAV platform that integrates MGS4 peptide‑guided capsid targeting with dual hypoxia‑responsive element (HRE)‑gated promoters driving Q‑CXCL9‑Fc (chemokine) and miR‑30‑based shRNA against mesothelin (MSLN).

1 Jun 2026

Trial shows safety of novel KIR-CAR T therapy in solid tumors

An innovative type of CAR T cell therapy, called KIR-CAR, was shown to be safe, with increasing efficacy corresponding to higher doses of the investigational treatment in nine patients with advanced ovarian cancer, mesothelioma or cholangiocarcinoma (bile duct cancer), according to an early report from an ongoing Phase I dose-escalation clinical trial.

20 Apr 2026

Talc not contaminated with asbestos shows no link to cancer

In a systematic review and meta-analysis, researchers found that occupational exposure to talc that is not contaminated with asbestos is not associated with an increase in the risk of lung cancer, mesothelioma, or laryngeal cancer.

10 Apr 2026

Engineered Listeria boosts innate immunity against cancer

After nearly 40 years of research on how Listeria bacteria manipulate our cells and battle our immune system to cause listeriosis, Daniel Portnoy and his colleagues have discovered a way to turn the bacteria into a potent booster of the immune system - and a potential weapon against cancer.

13 Feb 2026

$VT3989 shows promising antitumor activity in refractory mesothelioma patients$

VT3989 shows promising antitumor activity in refractory mesothelioma patients

The first-in-class YAP-TEAD inhibitor VT3989 continued to be well tolerated and demonstrated notable initial antitumor activity, particularly in patients with refractory mesothelioma, according to results from a trial led by researchers from The University of Texas MD Anderson Cancer Center.

22 Oct 2025

Combination immunotherapy prior to surgery shows encouraging results in mesothelioma

Results from an early phase clinical trial presented this week at the World Conference on Lung Cancer Meeting in Barcelona, Spain, and published in the Nature Medicine journal today [Monday, 8th September 2025] show that patients with mesothelioma - a rare cancer of the lining of the lung that may be caused by exposure to asbestos - who received a combination of two immunotherapy drugs, nivolumab and ipilimumab, before surgery had successful surgeries and encouraging early outcomes.

9 Sep 2025

New strategy for difficult-to-treat mesothelioma: Immunotherapy and ctDNA insights

People with operable diffuse pleural mesothelioma may benefit from immunotherapy before and after surgery, based on results of a clinical trial exploring the sequence of treatment and the role of surgery for this difficult to treat cancer.

8 Sep 2025

Breakthrough discovery reveals treatable form of familial mesothelioma

Researchers working independently at the University of Hawaii Cancer Center and the National Cancer Institute have discovered, and validated, a new variant of mesothelioma that may lead to more successful treatments.

2 Sep 2025

Dual epigenetic marks found to regulate cell identity

Shedding light on what determines how cells become what they are meant to be-nerves, bone, muscles, etc.-can also help researchers understand how diseases develop when these biological programs break down.

14 Aug 2025

Researchers pinpoint PRMT5 as a promising target for cancer drugs

A potential target for experimental drugs that block PRMT5 - a naturally occurring enzyme some tumors rely more on for survival - has been identified by researchers with the Fralin Biomedical Research Institute's Cancer Research Center in Washington, D.C.

26 Jul 2025

Gene expression study reveals clues to asbestos-linked mesothelioma

Gene expression leading to alterations in the DNA caused by asbestos exposure may explain the development of Malignant Pleural Mesothelioma (MPM), a rare and aggressive cancer.

31 May 2025

Six promising biomarkers could improve early and accurate detection of kidney injury

Critical Path Institute® (C-Path) and Boston Medical Center (BMC) published results for six biomarkers that could improve the early and accurate detection of kidney injury, leading to both the development of safer medications and better health outcomes for all patients.

28 Mar 2025

Future of cancer coverage for women federal firefighters uncertain under Trump

It took nearly three years to win presumptive workers' compensation coverage for breast, cervical, and other cancers that firefighters who work for federal agencies may develop because of hazardous exposures on the job.

28 Feb 2025

Insilico Medicine doses first patient in Phase I Trial of ISM6331 for mesothelioma

Insilico Medcine( "Insilico") , a clinical stage generative artificial intelligence (AI)-driven biotechnology company today announced the first patient has been dosed in the global multicenter Phase I Trial of ISM6331, a novel pan-TEAD inhibitor developed from Insilico's generative chemistry engine Chemistry42, for the treatment of mesothelioma and other solid tumors.

22 Jan 2025